Compare Garmin Ltd. (GRMN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Incyte Corporation — how do they compare? Garmin Ltd. trades at $309.51 (market cap $59.72B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Garmin Ltd. is far larger — about 2.4× Incyte Corporation's market cap, and Garmin Ltd. pays a 1.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| GRMN | INCY | |
|---|---|---|
Market Cap | $59.72B | $24.54B |
Sector | Technology | Health |
52-Week High | $313.16 | $129.93 |
52-Week Low | $187.10 | $81.61 |
Enterprise Value | $57.23B | $20.04B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $310.07, near its all-time high, with a slight daily decline of 0.99%. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing estimates of $2.30, and raised full-year guidance. Revenue growth remains robust, supported by strength in the fitness segment, while profitability metrics like a 60.08% gross margin highlight operational efficiency.
The outlook for GRMN is positive, driven by sustained demand in wearables and fitness technology, but risks include rich valuation multiples and potential growth deceleration. Analyst consensus is a 'Hold' with a $318.67 price target, suggesting limited near-term upside. Investors should weigh strong execution against premium pricing and competitive pressures in the consumer hardware space.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
